spironolactone orion 100 mg tablett
orion corporation - spironolakton - tablett - 100 mg - laktosmonohydrat hjälpämne; spironolakton 100 mg aktiv substans - spironolakton
aldactone 25 mg filmdragerad tablett
pfizer ab - spironolakton - filmdragerad tablett - 25 mg - spironolakton 25 mg aktiv substans - spironolakton
spironolakton orifarm 25 mg tablett
orifarm healthcare a/s - spironolakton - tablett - 25 mg - spironolakton 25 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne - spironolakton
spironolakton pfizer 25 mg tablett
pfizer ab - spironolakton - tablett - 25 mg - laktosmonohydrat hjälpämne; spironolakton 25 mg aktiv substans - spironolakton
spironolactone orion 25 mg tablett
orion corporation - spironolakton - tablett - 25 mg - spironolakton 25 mg aktiv substans; laktosmonohydrat hjälpämne - spironolakton
aldactone 50 mg filmdragerad tablett
pfizer ab - spironolakton - filmdragerad tablett - 50 mg - spironolakton 50 mg aktiv substans - spironolakton
spironolakton pfizer 50 mg tablett
pfizer ab - spironolakton - tablett - 50 mg - spironolakton 50 mg aktiv substans; laktosmonohydrat hjälpämne - spironolakton
spironolakton orifarm 50 mg tablett
orifarm healthcare a/s - spironolakton - tablett - 50 mg - laktosmonohydrat hjälpämne; spironolakton 50 mg aktiv substans; natriumlaurilsulfat hjälpämne - spironolakton
spironolactone orion 50 mg tablett
orion corporation - spironolakton - tablett - 50 mg - laktosmonohydrat hjälpämne; spironolakton 50 mg aktiv substans - spironolakton
qaialdo
nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 och 5.